secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001493152-24-028157
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus announces up to $10M convertible loan financing at 8% interest
------------------------------------------------------------------------

- Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.
- Loan bears 8% annual interest, matures in 12 months, convertible into Series D-1 Preferred at $2.8620/share.
- Series D-1 Preferred convertible into 10 shares of common stock per preferred share.
- Proceeds will fund drug discovery and development programs and G&A expenses.
- Also closed previously reported 2022 Financing totaling $4,865,500 as of July 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/0001493152-24-028157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer